HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —

Read more at globenewswire.com